Veraxa Biotech AG (VRXA)
NASDAQ: VRXAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VRXA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $147.06M
- EPS (TTM)
- -$0.57
- Dividend yield
- None
- 52-week range
- 0.90 – 27.36
- Day range
- 1.03 – 1.06
- Volume / Avg
- 114.63K / 267.82K
- Beta
- —
- Shares outstanding
- 141.41M
52-week range
VRXA stock today
On Nov 20, VRXA ended the session at $1.04, adding $0.01 (0.97%), versus the S&P 500's 3.70% decline. Trading was light, with 114.63K shares changing hands, about 43% of the average daily volume. Shares are 96.2% below their 52-week high of $27.36, set on Jun 11, 2026 and 15.6% above the 52-week low of $0.90, near the bottom of the past year's range.
VRXA is down 90.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 90.1%. Veraxa Biotech has posted a net loss over the last twelve months (EPS of -$0.57), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Veraxa Biotech
Company profileVeraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christoph Antz Ph.D.
- Headquarters
- Zurich
- Website
- veraxa.com
VRXA news
All VRXA newsVeraxa Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs VRXA |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs VRXA |
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs VRXA |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs VRXA |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs VRXA |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs VRXA |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs VRXA |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs VRXA |
Indexes, lists and sector
Veraxa Biotech stock FAQ
What is Veraxa Biotech's stock price today?
VRXA last traded at $1.04 as of Nov 20, 4:00 PM EST, up 0.97% on the day. Prices are delayed at least 15 minutes.
Who is Veraxa Biotech's CEO?
Dr. Christoph Antz Ph.D. is the chief executive officer of Veraxa Biotech AG.
What is the VRXA 52-week high?
The 52-week high for VRXA is $27.36 and the 52-week low is $0.90. The stock is currently 96.2% below its high.